Bayer has officially announced that new investigational datasets from its Phase III KERENDIA® (finerenone) clinical development program will be showcased at the 63rd European Renal Association (ERA) Congress, scheduled from June 3–6, 2026, in Glasgow, Scotland. The scientific presentations will highlight the first full results extracted from the Phase III FIND-CKD study alongside novel findings from the INFINITY pooled analysis, substantially expanding the evidence base validating KERENDIA across a diverse spectrum of chronic kidney disease (CKD) populations.
The documented clinical trial frameworks, global epidemiological landscapes, and current regulatory approval statuses include:
-
Core Clinical Trial Insights Slated for ERA 2026:
-
The FIND-CKD Clinical Trial: Bayer will deliver the inaugural comprehensive presentation of data captured from the global FIND-CKD trial. This study evaluated the therapeutic efficacy of adding KERENDIA to the standard of care in adult cohorts diagnosed with non-diabetic chronic kidney disease (nd-CKD). Concurrently, a prespecified subgroup analysis will be unveiled to examine the molecule’s clinical effects in patients living with glomerulonephritis, a complex cluster of inflammatory kidney disorders linked with progressive renal degradation.
-
The INFINITY Pooled Analysis: Investigators will reveal initial metrics from the INFINITY pooled analysis, which integrates data fields from three landmark Phase III studies: FIDELIO-DKD, FIGARO-DKD, and FIND-CKD. The architecture of this analysis is designed to thoroughly evaluate the real-world clinical impact of KERENDIA across an expansive range of CKD patient profiles, seamlessly bridging patients with CKD associated with type 2 diabetes (T2D) and those presenting with non-diabetic CKD.
-
-
Epidemiological Burden and Unmet Clinical Need in Nephrology: Chronic kidney disease represents an escalating global healthcare crisis, impacting an estimated 850 million individuals worldwide, with more than half of this global patient pool diagnosed with non-diabetic CKD. In the United States alone, the disease burden accounts for over 35 million affected individuals. CKD functions as a progressive pathology that can ultimately culminate in end-stage renal failure and severe adverse cardiovascular outcomes, yet sustainable therapeutic modalities remain critically limited for multiple patient cohorts. The upcoming data readouts are projected to offer crucial insights into the therapeutic utility of finerenone beyond conventional diabetic kidney disease pathways.
-
Current Regulatory Authorization Standing for KERENDIA: At present, KERENDIA maintains formal commercial approval from the U.S. Food and Drug Administration (FDA) for reducing the risk of progressive renal and major cardiovascular outcomes in adult patient populations experiencing chronic kidney disease associated with type 2 diabetes. Furthermore, the therapy is indicated and approved for use in adult patients presenting with heart failure characterized by a left ventricular ejection fraction (LVEF) of 40% or greater.